Companies: 10,795·Total market cap: $144.5T
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIVNASDAQHealthcare● Active
$28.86
+$0.28(+0.98%)
Market Cap$20.8B
P/E Ratio—
52W High$32.793
52W Low$10.705
Cash on HandFinancialsRevenue

Roivant Sciences Ltd. (ROIV) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ROIV · cash on hand · updated Mar 31, 2026

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$4.30B▼ -12.1% vs prior year
FY · as of Mar 31, 2026 · Reported in USD
Cash & Cash Equiv. (CCE)
$1.42B
cashAndCashEquivalents
Short-Term Investments
$2.87B
shortTermInvestments
YoY Change vs Prior Year
-12.1%
vs prior fiscal year
Latest Quarter
$4.30B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: March 31, 2026

Net cash vs debt

Cash & ST Investments$4.30BCash on Hand
Total Debt$107.4MTotal Debt
Net Cash / Net Debt+$4.19BNet Cash Position
Cash vs Debt Ratio
Cash 98%Debt 2%

Roivant Sciences Ltd. has a net cash position of $4.19B, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$4.30B − $107.4M = +$4.19B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ROIV annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Mar 31, 2026Latest$4.30B-12.1%
Mar 31, 2025$4.89B-25.3%
Mar 31, 2024$6.54B+288.9%
Mar 31, 2023$1.68B-18.4%
Mar 31, 2022$2.06B-3.4%
ROIV cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Roivant Sciences Ltd.
Roivant Sciences Ltd.YOU
ROIV
$4.30B20.9%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Roivant Sciences Ltd. (ROIV) cash on hand as of March 31, 2026 is $4.30B, comprising $1.42B in cash and cash equivalents (CCE) plus $2.87B in short-term investments — reported as Roivant Sciences Ltd. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Roivant Sciences Ltd. cash reserves or cash position.

Roivant Sciences Ltd. annual cash on hand history shows decreased -12.1% in 2026: decreased -12.1% in 2026. Roivant Sciences Ltd. cash reserves in 2026 reflect the company's capital allocation strategy.

Roivant Sciences Ltd. carries total debt of $107.4M against cash of $4.30B, resulting in a net cash position of +$4.19B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ROIV cash on hand · 5 questions

As of March 31, 2026, Roivant Sciences Ltd. (ROIV) has $4.30B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $1.42B in cash and cash equivalents (CCE) plus $2.87B in short-term investments. Latest quarter (March 31, 2026): $4.30B. Data sourced from the annual 10-K filing via FMP.

ROIV cash on handROIV cash reservesROIV cash 2026how much cash does ROIV have

▸ Source: FMP /balance-sheet-statement · US GAAP · Roivant Sciences Ltd. · Roivant Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: March 31, 2026